Need professional-grade analysis? Visit stockanalysis.com
$1.24B
3.57
55
N/A
Bicara Therapeutics Inc. Common Stock (BCAX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $24.01, up 0.33% from the previous close.
Over the past year, BCAX has traded between a low of $8.71 and a high of $24.01. The stock has gained 73.7% over this period. It is currently 175.7% above its 52-week low.
Bicara Therapeutics Inc. Common Stock has a market capitalization of $1.24B, with a price-to-earnings ratio of 3.57.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Side-by-side comparison against top Healthcare peers.